Abstract
Between May 1988 and March 1995, 359 children with acute myeloid leukaemia (AML) were treated in the MRC AML 10 trial. Three risk groups were identified based on cytogenetics and response to treatment. One hundred and twenty-five children relapsed – 103 in the bone marrow only, 12 in the bone marrow combined with other sites, and six had isolated extramedullary relapses (site was not known in four cases). Eighty-seven children received further combination chemotherapy, one all-trans retinoic acid for acute promyelocytic leukaemia, and one a matched unrelated donor allograft in relapse, and 61 achieved a second remission. One patient with no details on reinduction therapy also achieved second remission. Treatment in second remission varied – 44 children received a BMT (22 autografts, 12 matched unrelated donor allografts, 10 family donor allografts), and 17 were treated with chemotherapy alone. The overall survival rate for all children (treated and untreated) was 24% at 3 years, with a disease-free survival of 44% for those achieving a second remission. Length of first remission was the most important factor affecting response rates – children with a first remission of less than 1 year fared poorly (second remission rate 36%, 3 year survival 11%), whereas those with longer first remissions had a higher response rate (second remission rate 75%, 3 year survival 49%, P < 0.0001).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Webb, D., Wheatley, K., Harrison, G. et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia 13, 25–31 (1999). https://doi.org/10.1038/sj.leu.2401254
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401254
Keywords
This article is cited by
-
Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments
Pediatric Drugs (2014)
-
Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia
Pediatric Drugs (2014)
-
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol
International Journal of Hematology (2014)
-
Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan
Bone Marrow Transplantation (2010)